Clinical trial
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
NCT00224406 · Dompé Farmaceutici S.p.A, Industry · Completed
Key facts
| NCT number | NCT00224406 |
|---|---|
| Title | Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation |
| Official title | A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Repertaxin in the Prevention of Primary Graft Dysfunction After Lung Transplantation |
| Lead sponsor | Dompé Farmaceutici S.p.A, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ischemia-Reperfusion Injury, Lung Transplantation |
| Intervention type | Drug, Other |
| Interventions | Repertaxin, Placebo |
| Enrollment | 114 |
| Start date | May 1, 2005 |
| Primary completion | Sep 13, 2006 |
| Completion | Sep 13, 2007 |
| First posted | Sep 23, 2005 |
| Last update posted | Dec 11, 2024 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: